# Palivizumab

## Synagis inj 50mg/0.5mL

| 藥物代碼 | ISYNA1 |
| :--- | :--- |
| 適應症 | Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus \(RSV\) in pediatric patients at high risk of RSV disease, including infants with bronchopulmonary dysplasia, a history of premature birth \(&lt;=35 weeks gestational age\), & children with hemodynamically significant congenital heart disease. |
| 副作用 | Upper respiratory infections, otitis media, rhinitis, rash, pain, hernia, increased SGOT, pharyngitis. |
| 禁忌 | Hypersensitivity to palivizumab or humanized monoclonal antibodies. |
| 藥物保存方式 | 2-8 C |
| 用法用量 | Recommended Dose: 15 mg/kg IM \(preferably in anterolateral thigh\), given once a month during anticipated periods of RSV risk in the community |
| 肝功能異常 | 無需調整劑量  Infants and Children &lt;24 months: There are no dosage adjustments provided in the manufacturer's labeling. |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | No \(Limited\) Human Data - no relevant animal data |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Probably Compatible 無\(很少\)資料 - 可使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IM |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

